Skip to main content
SpringerLink
Log in

Targeted Therapy for Idiopathic Pulmonary Fibrosis: Where To Now?

  • Current Opinion
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Idiopathic pulmonary fibrosis (IPF) is an aging-associated, recalcitrant lung disease with historically limited therapeutic options. The recent approval of two drugs, pirfenidone and nintedanib, by the US Food and Drug Administration in 2014 has heralded a new era in its management. Both drugs have demonstrated efficacy in phase III clinical trials by retarding the rate of progression of IPF; neither drug appears to be able to completely arrest disease progression. Advances in the understanding of IPF pathobiology have led to an unprecedented expansion in the number of potential therapeutic targets. Drugs targeting several of these are under investigation in various stages of clinical development. Here, we provide a brief overview of the drugs that are currently approved and others in phase II clinical trials. Future therapeutic opportunities that target novel pathways, including some that are associated with the biology of aging, are examined. A multi-targeted approach, potentially with combination therapies, and identification of individual patients (or subsets of patients) who may respond more favourably to specific agents are likely to be more effective.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Thannickal VJ, Flaherty KR, Martinez FJ, Lynch JP 3rd. Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy. Expert Opin Pharmacother. 2004;5(8):1671–86.

    Article  CAS  PubMed  Google Scholar 

  2. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161(2 Pt 1):646–64.

  3. American Thoracic Society. European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS Board of Directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165(2):277–304.

    Article  Google Scholar 

  4. Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev. 2012;21(126):355–61.

    Article  PubMed  Google Scholar 

  5. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174(7):810–6.

    Article  PubMed  Google Scholar 

  6. Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968–77.

    Article  Google Scholar 

  7. King TE Jr, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(1):92–9.

    Article  PubMed  Google Scholar 

  8. King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet. 2009;374(9685):222–8.

    Article  CAS  PubMed  Google Scholar 

  9. Network Idiopathic Pulmonary Fibrosis Clinical Research, Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010;363(7):620–8.

    Article  Google Scholar 

  10. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192(2):e3–19.

    Article  PubMed  Google Scholar 

  11. Ding Q, Luckhardt T, Hecker L, Zhou Y, Liu G, Antony VB, et al. New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis. Drugs. 2011;71(8):981–1001.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Ahluwalia N, Shea BS, Tager AM. New therapeutic targets in idiopathic pulmonary fibrosis: aiming to rein in runaway wound-healing responses. Am J Respir Crit Care Med. 2014;190(8):867–78.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Woodcock HV, Maher TM. The treatment of idiopathic pulmonary fibrosis. F1000Prime Rep. 2014;6:16.

  14. Thannickal VJ, Murthy M, Balch WE, Chandel NS, Meiners S, Eickelberg O, et al. Blue Journal Conference. Aging and susceptibility to lung disease. Am J Respir Crit Care Med. 2015;191(3):261–9.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Thannickal VJ. Mechanistic links between aging and lung fibrosis. Biogerontology. 2013;14(6):609–15.

    Article  CAS  PubMed  Google Scholar 

  16. Raghu G, Chen SY, Yeh WS, Maroni B, Li Q, Lee YC, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–11. Lancet Respir Med. 2014;2(7):566–72.

    Article  PubMed  Google Scholar 

  17. Fell CD, Martinez FJ, Liu LX, Murray S, Han MK, Kazerooni EA, et al. Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2010;181(8):832–7.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Collard HR. The age of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2010;181(8):771–2.

    Article  PubMed  Google Scholar 

  19. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194–217.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Thannickal VJ, Zhou Y, Gaggar A, Duncan SR. Fibrosis: ultimate and proximate causes. J Clin Invest. 2014;124(11):4673–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Thannickal VJ, Toews GB, White ES, Lynch JP 3rd, Martinez FJ. Mechanisms of pulmonary fibrosis. Annu Rev Med. 2004;55:395–417.

    Article  CAS  PubMed  Google Scholar 

  22. Iyer SN, Wild JS, Schiedt MJ, Hyde DM, Margolin SB, Giri SN. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med. 1995;125(6):779–85.

    CAS  PubMed  Google Scholar 

  23. Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev. 2011;20(120):85–97.

    Article  CAS  PubMed  Google Scholar 

  24. Trivedi R, Redente EF, Thakur A, Riches DW, Kompella UB. Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice. Nanotechnology. 2012;23(50):505101.

    Article  PubMed  CAS  Google Scholar 

  25. Maher TM. Pirfenidone in idiopathic pulmonary fibrosis. Drugs Today (Barc). 2010;46(7):473–82.

    Article  CAS  PubMed  Google Scholar 

  26. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–92.

    Article  PubMed  CAS  Google Scholar 

  27. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–9.

    Article  CAS  PubMed  Google Scholar 

  28. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68(12):4774–82.

    Article  CAS  PubMed  Google Scholar 

  29. Chaudhary NI, Roth GJ, Hilberg F, Muller-Quernheim J, Prasse A, Zissel G, et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J. 2007;29(5):976–85.

    Article  CAS  PubMed  Google Scholar 

  30. McCormack PL. Nintedanib: first global approval. Drugs. 2015;75(1):129–39.

    Article  PubMed  CAS  Google Scholar 

  31. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079–87.

    Article  CAS  PubMed  Google Scholar 

  32. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82.

    Article  PubMed  CAS  Google Scholar 

  33. Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther. 2014;349(2):209–20.

    Article  PubMed  CAS  Google Scholar 

  34. Wollin L, Wex E, Pautsch A, Schnapp G, Hostettler KE, Stowasser S, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45(5):1434–45.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Rangarajan S, Kurundkar A, Kurundkar D, Bernard K, Sanders YY, Ding Q, et al. Novel mechanisms for the anti-fibrotic action of nintedanib. Am J Respir Cell Mol Biol (Epub 2015 Jun 13).

  36. Loveman E, Copley VR, Scott DA, Colquitt JL, Clegg AJ, O’Reilly KM. Comparing new treatments for idiopathic pulmonary fibrosis—a network meta-analysis. BMC Pulm Med. 2015;15:37.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  37. Loveman E, Copley VR, Colquitt JL, Scott DA, Clegg AJ, Jones J, et al. The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation. BMC Pharmacol Toxicol. 2014;15:63.

    Article  PubMed Central  PubMed  Google Scholar 

  38. Hancock A, Armstrong L, Gama R, Millar A. Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am J Respir Cell Mol Biol. 1998;18(1):60–5.

    Article  CAS  PubMed  Google Scholar 

  39. Cieslik KA, Taffet GE, Carlson S, Hermosillo J, Trial J, Entman ML. Immune-inflammatory dysregulation modulates the incidence of progressive fibrosis and diastolic stiffness in the aging heart. J Mol Cell Cardiol. 2011;50(1):248–56.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med. 2001;194(6):809–21.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  41. Lee JH, Kaminski N, Dolganov G, Grunig G, Koth L, Solomon C, et al. Interleukin-13 induces dramatically different transcriptional programs in three human airway cell types. Am J Respir Cell Mol Biol. 2001;25(4):474–85.

    Article  CAS  PubMed  Google Scholar 

  42. Zhu Z, Ma B, Zheng T, Homer RJ, Lee CG, Charo IF, et al. IL-13-induced chemokine responses in the lung: role of CCR2 in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol. 2002;168(6):2953–62.

    Article  CAS  PubMed  Google Scholar 

  43. Murray LA, Argentieri RL, Farrell FX, Bracht M, Sheng H, Whitaker B, et al. Hyper-responsiveness of IPF/UIP fibroblasts: interplay between TGFbeta1, IL-13 and CCL2. Int J Biochem Cell Biol. 2008;40(10):2174–82.

    Article  CAS  PubMed  Google Scholar 

  44. Murray LA, Zhang H, Oak SR, Coelho AL, Herath A, Flaherty KR, et al. Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model. Am J Respir Cell Mol Biol. 2014;50(5):985–94.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  45. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med. 2006;12(1):99–106.

    Article  CAS  PubMed  Google Scholar 

  46. Lumsden RV, Worrell JC, Boylan D, Walsh SM, Cramton J, Counihan I, et al. Modulation of pulmonary fibrosis by IL-13Ralpha2. Am J Physiol Lung Cell Mol Physiol. 2015;308(7):L710–8.

    Article  CAS  PubMed  Google Scholar 

  47. Baran CP, Opalek JM, McMaken S, Newland CA, O’Brien JM Jr, Hunter MG, et al. Important roles for macrophage colony-stimulating factor, CC chemokine ligand 2, and mononuclear phagocytes in the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176(1):78–89.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  48. Liu X, Das AM, Seideman J, Griswold D, Afuh CN, Kobayashi T, et al. The CC chemokine ligand 2 (CCL2) mediates fibroblast survival through IL-6. Am J Respir Cell Mol Biol. 2007;37(1):121–8.

    Article  CAS  PubMed  Google Scholar 

  49. Moore BB, Murray L, Das A, Wilke CA, Herrygers AB, Toews GB. The role of CCL12 in the recruitment of fibrocytes and lung fibrosis. Am J Respir Cell Mol Biol. 2006;35(2):175–81.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  50. Kalderen C, Stadler C, Forsgren M, Kvastad L, Johansson E, Sydow-Backman M, et al. CCL2 mediates anti-fibrotic effects in human fibroblasts independently of CCR2. Int Immunopharmacol. 2014;20(1):66–73.

    Article  CAS  PubMed  Google Scholar 

  51. Raghu G, Martinez FJ, Brown KK, Costabel U, Cottin V, Wells AU, et al. A phase II, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study of the safety and efficacy of CNTO 888 (carlumab) in patients with idiopathic pulmonary fibrosis [abstract]. Am J Respir Crit Care Med. 2013;187:A3376.

  52. Duncan MR, Frazier KS, Abramson S, Williams S, Klapper H, Huang X, et al. Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down-regulation by cAMP. FASEB J. 1999;13(13):1774–86.

    CAS  PubMed  Google Scholar 

  53. Grotendorst GR. Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev. 1997;8(3):171–9.

    Article  CAS  PubMed  Google Scholar 

  54. Allen JT, Knight RA, Bloor CA, Spiteri MA. Enhanced insulin-like growth factor binding protein-related protein 2 (connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Cell Mol Biol. 1999;21(6):693–700.

    Article  CAS  PubMed  Google Scholar 

  55. Pan LH, Yamauchi K, Uzuki M, Nakanishi T, Takigawa M, Inoue H, et al. Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF. Eur Respir J. 2001;17(6):1220–7.

    Article  CAS  PubMed  Google Scholar 

  56. Lasky JA, Ortiz LA, Tonthat B, Hoyle GW, Corti M, Athas G, et al. Connective tissue growth factor mRNA expression is upregulated in bleomycin-induced lung fibrosis. Am J Physiol. 1998;275(2 Pt 1):L365–71.

    CAS  PubMed  Google Scholar 

  57. Lipson KE, Wong C, Teng Y, Spong S. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair. 2012;5(Suppl 1):S24.

    Article  PubMed Central  PubMed  Google Scholar 

  58. Raghu G, Scholand MB, De Andrade J, Lancaster L, Mageto YN, Goldin JG, et al. Safety and efficacy of anti-CTGF monoclonal antibody FG-3019 for treatment of idiopathic pulmonary fibrosis (IPF): results of phase 2 clinical trial two years after initiation [abstract]. Am J Respir Crit Care Med. 2014;189:A1426.

  59. Pinnell SR, Martin GR. The cross-linking of collagen and elastin: enzymatic conversion of lysine in peptide linkage to alpha-aminoadipic-delta-semialdehyde (allysine) by an extract from bone. Proc Natl Acad Sci USA. 1968;61(2):708–16.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  60. Siegel RC, Pinnell SR, Martin GR. Cross-linking of collagen and elastin: properties of lysyl oxidase. Biochemistry. 1970;9(23):4486–92.

    Article  CAS  PubMed  Google Scholar 

  61. Barry-Hamilton V, Spangler R, Marshall D, McCauley S, Rodriguez HM, Oyasu M, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med. 2010;16(9):1009–17.

    Article  CAS  PubMed  Google Scholar 

  62. Chien JW, Richards TJ, Gibson KF, Zhang Y, Lindell KO, Shao L, et al. Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression. Eur Respir J. 2014;43(5):1430–8.

    Article  CAS  PubMed  Google Scholar 

  63. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994;331(19):1286–92.

    Article  CAS  PubMed  Google Scholar 

  64. Pardali K, Moustakas A. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta. 2007;1775(1):21–62.

    CAS  PubMed  Google Scholar 

  65. Munger JS, Harpel JG, Gleizes PE, Mazzieri R, Nunes I, Rifkin DB. Latent transforming growth factor-beta: structural features and mechanisms of activation. Kidney Int. 1997;51(5):1376–82.

    Article  CAS  PubMed  Google Scholar 

  66. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell. 1999;96(3):319–28.

    Article  CAS  PubMed  Google Scholar 

  67. Puthawala K, Hadjiangelis N, Jacoby SC, Bayongan E, Zhao Z, Yang Z, et al. Inhibition of integrin alpha(v)beta6, an activator of latent transforming growth factor-beta, prevents radiation-induced lung fibrosis. Am J Respir Crit Care Med. 2008;177(1):82–90.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  68. Horan GS, Wood S, Ona V, Li DJ, Lukashev ME, Weinreb PH, et al. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med. 2008;177(1):56–65.

    Article  CAS  PubMed  Google Scholar 

  69. Shea BS, Tager AM. Role of the lysophospholipid mediators lysophosphatidic acid and sphingosine 1-phosphate in lung fibrosis. Proc Am Thorac Soc. 2012;9(3):102–10.

    Article  CAS  PubMed  Google Scholar 

  70. Pradere JP, Klein J, Gres S, Guigne C, Neau E, Valet P, et al. LPA1 receptor activation promotes renal interstitial fibrosis. J Am Soc Nephrol. 2007;18(12):3110–8.

    Article  CAS  PubMed  Google Scholar 

  71. Tager AM, LaCamera P, Shea BS, Campanella GS, Selman M, Zhao Z, et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med. 2008;14(1):45–54.

    Article  CAS  PubMed  Google Scholar 

  72. Castelino FV, Seiders J, Bain G, Brooks SF, King CD, Swaney JS, et al. Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma. Arthritis Rheum. 2011;63(5):1405–15.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  73. Sakai N, Chun J, Duffield JS, Wada T, Luster AD, Tager AM. LPA1-induced cytoskeleton reorganization drives fibrosis through CTGF-dependent fibroblast proliferation. FASEB J. 2013;27(5):1830–46.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  74. Hirokawa K. Autoimmunity and aging. Concepts Immunopathol. 1985;1:251–88.

    CAS  PubMed  Google Scholar 

  75. Prelog M. Aging of the immune system: a risk factor for autoimmunity? Autoimmun Rev. 2006;5(2):136–9.

    Article  CAS  PubMed  Google Scholar 

  76. Donahoe M, Valentine VG, Chien N, Gibson KF, Raval JS, Saul M, et al. Autoantibody-targeted treatments for acute exacerbations of idiopathic pulmonary fibrosis. PLoS One. 2015;10(6):e0127771.

    Article  PubMed Central  PubMed  Google Scholar 

  77. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Paliogianni F, Sirinian C, et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol. 2012;30(2 Suppl 71):S17–22.

  78. Leon RJ, Gonsalvo A, Salas R, Hidalgo NC. Rituximab-induced acute pulmonary fibrosis. Mayo Clin Proc. 2004;79(7):949, 53.

  79. Chaumais MC, Garnier A, Chalard F, Peuchmaur M, Dauger S, Jacqz-Agrain E, et al. Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol. 2009;24(9):1753–5.

    Article  PubMed  Google Scholar 

  80. Rathi M, Ramachandran R, Gundlapalli S, Agarwal R, Das A, Kumar V, et al. Rituximab induced pulmonary fibrosis in a patient with lupus nephritis. Lupus. 2012;21(10):1131–4.

    Article  CAS  PubMed  Google Scholar 

  81. Ryter SW, Choi AM. Therapeutic applications of carbon monoxide in lung disease. Curr Opin Pharmacol. 2006;6(3):257–62.

    Article  CAS  PubMed  Google Scholar 

  82. Kohmoto J, Nakao A, Kaizu T, Tsung A, Ikeda A, Tomiyama K, et al. Low-dose carbon monoxide inhalation prevents ischemia/reperfusion injury of transplanted rat lung grafts. Surgery. 2006;140(2):179–85.

    Article  PubMed  Google Scholar 

  83. Hoetzel A, Dolinay T, Vallbracht S, Zhang Y, Kim HP, Ifedigbo E, et al. Carbon monoxide protects against ventilator-induced lung injury via PPAR-gamma and inhibition of Egr-1. Am J Respir Crit Care Med. 2008;177(11):1223–32.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  84. Hoetzel A, Schmidt R, Vallbracht S, Goebel U, Dolinay T, Kim HP, et al. Carbon monoxide prevents ventilator-induced lung injury via caveolin-1. Crit Care Med. 2009;37(5):1708–15.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  85. Chiang N, Shinohara M, Dalli J, Mirakaj V, Kibi M, Choi AM, et al. Inhaled carbon monoxide accelerates resolution of inflammation via unique proresolving mediator-heme oxygenase-1 circuits. J Immunol. 2013;190(12):6378–88.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  86. Zhou Z, Song R, Fattman CL, Greenhill S, Alber S, Oury TD, et al. Carbon monoxide suppresses bleomycin-induced lung fibrosis. Am J Pathol. 2005;166(1):27–37.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  87. Han MK, Zhou Y, Murray S, Tayob N, Noth I, Lama VN, et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med. 2014;2(7):548–56.

    Article  PubMed Central  PubMed  Google Scholar 

  88. Molyneaux PL, Cox MJ, Willis-Owen SA, Mallia P, Russell KE, Russell AM, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2014;190(8):906–13.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  89. Wootton SC, Kim DS, Kondoh Y, Chen E, Lee JS, Song JW, et al. Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(12):1698–702.

    Article  PubMed Central  PubMed  Google Scholar 

  90. Wuyts WA, Willems S, Vos R, Vanaudenaerde BM, De Vleeschauwer SI, Rinaldi M, et al. Azithromycin reduces pulmonary fibrosis in a bleomycin mouse model. Exp Lung Res. 2010;36(10):602–14.

    Article  CAS  PubMed  Google Scholar 

  91. Shulgina L, Cahn AP, Chilvers ER, Parfrey H, Clark AB, Wilson EC, et al. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial. Thorax. 2013;68(2):155–62.

    Article  PubMed  Google Scholar 

  92. Leung T, Manser E, Tan L, Lim L. A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. J Biol Chem. 1995;270(49):29051–4.

    Article  CAS  PubMed  Google Scholar 

  93. Riento K, Ridley AJ. ROCKs: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol. 2003;4(6):446–56.

    Article  CAS  PubMed  Google Scholar 

  94. Street CA, Bryan BA. Rho kinase proteins—pleiotropic modulators of cell survival and apoptosis. Anticancer Res. 2011;31(11):3645–57.

    PubMed Central  CAS  PubMed  Google Scholar 

  95. Zhou Y, Huang X, Hecker L, Kurundkar D, Kurundkar A, Liu H, et al. Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. J Clin Invest. 2013;123(3):1096–108.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  96. Wang P, Tang F, Li R, Zhang H, Chen S, Liu P, et al. Contribution of different Nox homologues to cardiac remodeling in two-kidney two-clip renovascular hypertensive rats: effect of valsartan. Pharmacol Res. 2007;55(5):408–17.

    Article  CAS  PubMed  Google Scholar 

  97. Masamune A, Kikuta K, Watanabe T, Satoh K, Hirota M, Shimosegawa T. Hypoxia stimulates pancreatic stellate cells to induce fibrosis and angiogenesis in pancreatic cancer. Am J Physiol Gastrointest Liver Physiol. 2008;295(4):G709–17.

    Article  CAS  PubMed  Google Scholar 

  98. Hecker L, Vittal R, Jones T, Jagirdar R, Luckhardt TR, Horowitz JC, et al. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med. 2009;15(9):1077–81.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  99. Amara N, Goven D, Prost F, Muloway R, Crestani B, Boczkowski J. NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFbeta1-induced fibroblast differentiation into myofibroblasts. Thorax. 2010;65(8):733–8.

    Article  PubMed Central  PubMed  Google Scholar 

  100. Kuroda J, Ago T, Matsushima S, Zhai P, Schneider MD, Sadoshima J. NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc Natl Acad Sci USA. 2010;107(35):15565–70.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  101. Sancho P, Mainez J, Crosas-Molist E, Roncero C, Fernandez-Rodriguez CM, Pinedo F, et al. NADPH oxidase NOX4 mediates stellate cell activation and hepatocyte cell death during liver fibrosis development. PLoS One. 2012;7(9):e45285.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  102. Thannickal VJ, Fanburg BL. Activation of an H2O2-generating NADH oxidase in human lung fibroblasts by transforming growth factor beta 1. J Biol Chem. 1995;270(51):30334–8.

    Article  CAS  PubMed  Google Scholar 

  103. Cheng G, Cao Z, Xu X, van Meir EG, Lambeth JD. Homologs of gp91phox: cloning and tissue expression of Nox3, Nox4, and Nox5. Gene. 2001;269(1–2):131–40.

    Article  CAS  PubMed  Google Scholar 

  104. Thannickal VJ. Aging, antagonistic pleiotropy and fibrotic disease. Int J Biochem Cell Biol. 2010;42(9):1398–400.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  105. Thannickal VJ. Mechanisms of pulmonary fibrosis: role of activated myofibroblasts and NADPH oxidase. Fibrogenesis Tissue Repair. 2012;5(Suppl 1):S23.

    Article  PubMed Central  PubMed  Google Scholar 

  106. Sanders YY, Liu H, Liu G, Thannickal VJ. Epigenetic mechanisms regulate NADPH oxidase-4 expression in cellular senescence. Free Radic Biol Med. 2015;79:197–205.

    Article  CAS  PubMed  Google Scholar 

  107. Hecker L, Logsdon NJ, Kurundkar D, Kurundkar A, Bernard K, Hock T, et al. Reversal of persistent fibrosis in aging by targeting Nox4–Nrf2 redox imbalance. Sci Transl Med. 2014;6(231):231ra47.

  108. Salminen A, Kaarniranta K. AMP-activated protein kinase (AMPK) controls the aging process via an integrated signaling network. Ageing Res Rev. 2012;11(2):230–41.

    Article  CAS  PubMed  Google Scholar 

  109. Rangarajan S, Liu Y, Park DW, Zmijewska A, Abraham E, Thannickal VJ, et al. AMP-activated protein kinase activation diminishes the severity of experimental lung fibrosis [abstract]. Am J Respir Crit Care Med. 2015;191:A3474.

  110. Mihaylova MM, Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol. 2011;13(9):1016–23.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  111. Burkewitz K, Zhang Y, Mair WB. AMPK at the nexus of energetics and aging. Cell Metab. 2014;20(1):10–25.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  112. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest. 2004;114(9):1308–16.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  113. Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR, et al. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med. 2010;181(6):604–10.

    Article  CAS  PubMed  Google Scholar 

  114. Vittal R, Horowitz JC, Moore BB, Zhang H, Martinez FJ, Toews GB, et al. Modulation of prosurvival signaling in fibroblasts by a protein kinase inhibitor protects against fibrotic tissue injury. Am J Pathol. 2005;166(2):367–75.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  115. Vittal R, Zhang H, Han MK, Moore BB, Horowitz JC, Thannickal VJ. Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases. J Pharmacol Exp Ther. 2007;321(1):35–44.

    Article  CAS  PubMed  Google Scholar 

  116. Garneau-Tsodikova S, Thannickal VJ. Protein kinase inhibitors in the treatment of pulmonary fibrosis. Curr Med Chem. 2008;15(25):2632–40.

    Article  CAS  PubMed  Google Scholar 

  117. Grimminger F, Gunther A, Vancheri C. The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45(5):1426–33.

    Article  CAS  PubMed  Google Scholar 

  118. Hu M, Che P, Han X, Cai GQ, Liu G, Antony V, et al. Therapeutic targeting of Src kinase in myofibroblast differentiation and pulmonary fibrosis. J Pharmacol Exp Ther. 2014;351(1):87–95.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  119. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.

    Article  CAS  PubMed  Google Scholar 

  120. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 2010;466(7308):835–40.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  121. Cui H, Xie N, Thannickal VJ, Liu G. The code of non-coding RNAs in lung fibrosis. Cell Mol Life Sci. 2015;72(18):3507–19.

    Article  CAS  PubMed  Google Scholar 

  122. Cushing L, Kuang PP, Qian J, Shao F, Wu J, Little F, et al. miR-29 is a major regulator of genes associated with pulmonary fibrosis. Am J Respir Cell Mol Biol. 2011;45(2):287–94.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  123. Yang T, Liang Y, Lin Q, Liu J, Luo F, Li X, et al. miR-29 mediates TGFbeta1-induced extracellular matrix synthesis through activation of PI3K–AKT pathway in human lung fibroblasts. J Cell Biochem. 2013;114(6):1336–42.

    Article  CAS  PubMed  Google Scholar 

  124. Liu G, Friggeri A, Yang Y, Milosevic J, Ding Q, Thannickal VJ, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med. 2010;207(8):1589–97.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  125. van Rooij E, Kauppinen S. Development of microRNA therapeutics is coming of age. EMBO Mol Med. 2014;6(7):851–64.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  126. Morry J, Ngamcherdtrakul W, Gu S, Goodyear SM, Castro DJ, Reda MM, et al. Dermal delivery of HSP47 siRNA with NOX4-modulating mesoporous silica-based nanoparticles for treating fibrosis. Biomaterials. 2015;66:41–52.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, 1900 University Blvd THT 422, Birmingham, AL, 35294-2180, USA

    Sunad Rangarajan, Morgan L. Locy, Tracy R. Luckhardt & Victor J. Thannickal

Authors
  1. Sunad Rangarajan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Morgan L. Locy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tracy R. Luckhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Victor J. Thannickal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Victor J. Thannickal.

Ethics declarations

Funding

No specific sources of funding were used to support the writing of this manuscript.

Conflicts of Interest

Tracy Luckhardt participated in an Advisory Board for Intermune Inc. (the manufacturer of pirfenidone) in June 2014 and received an honorarium and travel expenses. Sunad Rangarajan, Morgan Locy and Victor Thannickal have no conflicts of interest to report.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rangarajan, S., Locy, M.L., Luckhardt, T.R. et al. Targeted Therapy for Idiopathic Pulmonary Fibrosis: Where To Now?. Drugs 76, 291–300 (2016). https://doi.org/10.1007/s40265-015-0523-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-015-0523-6

Keywords

Search

Navigation